...
首页> 外文期刊>Human reproduction update >Misoprostol prior to hysteroscopy in premenopausal and post-menopausal women. A systematic review and meta-analysis
【24h】

Misoprostol prior to hysteroscopy in premenopausal and post-menopausal women. A systematic review and meta-analysis

机译:绝经前和绝经后妇女宫腔镜检查前米索前列醇。系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Although several randomized controlled trials (RCTs) have examined the effect of misoprostol prior to hysteroscopy for cervical dilatation, no solid conclusion has been reached. We therefore set out to perform a meta-analysis of RCTs. Methods: We searched MEDLINE, the ISI Web of Science and the Cochrane Library to identify RCTs comparing misoprostol versus placebo or control prior to hysteroscopy. No restrictions on language or time were applied. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated for all dichotomous outcomes, whereas mean differences (MDs) and 95% CIs were calculated for continuous outcomes using the Mantel-Haenszel or DerSimonian-Laird model according to the heterogeneity. Results: Of the initial 141 potentially relevant articles that were retrieved, 21 RCTs involving 1786 patients were included in the meta-analysis. Subgroup analyses were performed according to menopausal status and according to whether diagnostic or operative hysteroscopy was performed. Premenopausal women treated with misoprostol had a significantly lower risk for further cervical dilatation in the diagnostic setting [RR (95% CI): 0.56 (0.34-0.92)] and a significantly lower risk for cervical laceration in the operative setting [RR (95% CI): 0.22 (0.09-0.54)], compared with placebo. In contrast, post-menopausal patients did not experience any clear benefit from misoprostol compared with placebo regarding the need for further cervical dilatation [RR (95% CI): 0.99 (0.76-1.30)] and the cervical laceration rate [RR (95% CI): 1.15 (0.40-3.29)]. In addition, the mean cervical width prior to hysteroscopy was significantly higher in premenopausal women treated with misoprostol compared with placebo [MD (95% CI): 2.47 mm (1.81-3.13)] but did not differ among post-menopausal patients [MD (95% CI): 0.39 mm (-0.42 to 1.21)]. Conclusions: Misoprostol prior to hysteroscopy appears to facilitate an easier and uncomplicated procedure only in premenopausal women.
机译:背景:尽管有几项随机对照试验(RCT)已经在宫腔镜检查之前对米索前列醇进行宫颈扩张术的效果进行了检查,但尚无确切结论。因此,我们着手进行RCT的荟萃分析。方法:我们在MEDLINE,ISI Web of Science和Cochrane库中进行搜索,以鉴定将米索前列醇与安慰剂或宫腔镜检查前对照进行比较的RCT。没有语言或时间上的限制。根据异质性,使用Mantel-Haenszel或DerSimonian-Laird模型计算所有二分结果的相对风险(RRs)和95%置信区间(CIs),而计算连续结果的平均差异(MDs)和95%CIs。结果:在最初检索的141篇潜在相关文章中,荟萃分析包括21篇涉及1786例患者的RCT。根据更年期状态以及是否进行诊断性或宫腔镜检查进行亚组分析。接受米索前列醇治疗的绝经前妇女在诊断环境中进一步宫颈扩张的风险显着较低[RR(95%CI):0.56(0.34-0.92)],在手术环境中发生宫颈裂伤的风险显着较低[RR(95%) CI):0.22(0.09-0.54)],与安慰剂相比。相比之下,绝经后患者与米索前列醇相比安慰剂在进一步子宫颈扩张[RR(95%CI):0.99(0.76-1.30)]和子宫颈裂伤率[RR(95%) CI:1.15(0.40-3.29)]。此外,接受米索前列醇治疗的绝经前妇女的宫腔镜检查前平均宫颈宽度明显高于安慰剂[MD(95%CI):2.47 mm(1.81-3.13)],但绝经后患者之间无差异[MD( 95%CI):0.39毫米(-0.42至1.21)。结论:宫腔镜检查前的米索前列醇似乎仅对绝经前妇女有利于简化和简化手术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号